Esperion Therapeutics Inc.(ESPR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ESPR Esperion Therapeutics Inc.

休市中 01-02 16:00:00 EST

3.71

+0.01

+0.27%

盘后3.74

+0.03+0.81%

19:28 EST

最高3.89	最低3.65	成交量496.71万
今开3.86	昨收3.70	日振幅6.48%
总市值8.87亿	流通市值8.79亿	总股本2.39亿
成交额1,855万	换手率2.10%	流通股本2.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics Inc.","latestPrice":3.71,"timestamp":1767387600000,"preClose":3.7,"halted":0,"volume":4967078,"hourTrading":{"tag":"盘后","latestPrice":3.7401,"preClose":3.71,"latestTime":"19:28 EST","volume":1408751,"amount":5226930.0898,"timestamp":1767400102508},"delay":0,"floatShares":237000000,"shares":239063437,"eps":-0.535792,"marketStatus":"休市中","change":0.01,"latestTime":"01-02 16:00:00 EST","open":3.86,"high":3.8899,"low":3.65,"amount":18549700.3132166,"amplitude":0.064838,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.535792,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767603600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":3.7,"preHourTrading":{"tag":"盘前","latestPrice":3.9,"preClose":3.7,"latestTime":"09:29 EST","volume":37396,"amount":145244.1942,"timestamp":1767364167039},"postHourTrading":{"tag":"盘后","latestPrice":3.7401,"preClose":3.71,"latestTime":"19:28 EST","volume":1408751,"amount":5226930.0898,"timestamp":1767400102508},"volumeRatio":1.4309504507449478,"impliedVol":0.6873,"impliedVolPercentile":0.348},"requestUrl":"/m/hq/s/ESPR","defaultTab":"news","newsList":[{"id":"1142792424","title":"Esperion Therapeutics：还可根据大冢在日本的总净销售额成就获得额外的销售里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1142792424","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142792424?lang=zh_cn&edition=full","pubTime":"2025-11-21 21:06","pubTimestamp":1763730402,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics：还可根据大冢在日本的总净销售额成就获得额外的销售里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"1190396006","title":"Esperion Therapeutics：根据协议，Esperion因近期Otsuka的成就将获得9000万美元的近期付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1190396006","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190396006?lang=zh_cn&edition=full","pubTime":"2025-11-21 21:05","pubTimestamp":1763730316,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics：根据协议，Esperion因近期Otsuka的成就将获得9000万美元的近期付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"1198148930","title":"异动解读 | Esperion Therapeutics盘中大涨5.26%，新数据将在AHA科学会议上展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1198148930","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198148930?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:08","pubTimestamp":1762787310,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc.今日盘中大涨5.26%，引起投资者广泛关注。根据公司最新公告，Esperion将在2025年美国心脏协会科学会议上通过口头和海报演示展示其主打产品Nexletol的最新研究数据。AHA科学会议是心血管领域最具影响力的学术会议之一，Esperion在此展示Nexletol的新数据意义重大。Nexletol是一种用于降低胆固醇的创新药物，新数据的公布可能会进一步证实其临床效果和安全性。投资者对这一潜在的积极发展做出了乐观反应，推动了Esperion股价的大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ESPR"],"gpt_icon":0},{"id":"1196636131","title":"Esperion宣布在2025年AHA科学会议上通过口头和海报演示展示Nexletol®（Bempedoic Acid）的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1196636131","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196636131?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:03","pubTimestamp":1762779794,"startTime":"0","endTime":"0","summary":"Esperion宣布在2025年AHA科学会议上通过口头和海报演示展示Nexletol®（Bempedoic Acid）的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"1123193546","title":"Esperion Therapeutics Inc重申其对2025财年运营开支的预期在2.15亿到2.35亿美元之间","url":"https://stock-news.laohu8.com/highlight/detail?id=1123193546","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123193546?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:04","pubTimestamp":1762427078,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc重申其对2025财年运营开支的预期在2.15亿到2.35亿美元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"1106714850","title":"Esperion Therapeutics预计将于2026年第一季度实现可持续盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1106714850","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106714850?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:04","pubTimestamp":1762427048,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics预计将于2026年第一季度实现可持续盈利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"1150423458","title":"新闻稿：Esperion任命行业资深人士John Harlow为首席商业官","url":"https://stock-news.laohu8.com/highlight/detail?id=1150423458","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150423458?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:03","pubTimestamp":1762261412,"startTime":"0","endTime":"0","summary":"安阿伯，密歇根州，2025年11月4日-- Esperion今日宣布，John Harlow已被任命为公司的首席商业官，任职时间从2025年11月17日生效。Harlow先生将加入Esperion的执行领导团队，并直接向Esperion的总裁兼首席执行官Sheldon Koenig汇报。本新闻稿中包含的任何明确或隐含的非历史事实声明可能被视为前瞻性声明。本新闻稿中包含的任何前瞻性声明仅在此日期时有效，Esperion不承担任何更新或修订本新闻稿中包含的前瞻性声明的义务或承诺，除非法律要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","R","BK4232","BK4022","ESPR"],"gpt_icon":0},{"id":"1132902985","title":"Esperion Therapeutics Inc - Esp-2001 可能符合FDA的孤儿药和快速通道认证资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1132902985","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132902985?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:08","pubTimestamp":1760616489,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc - Esp-2001 可能符合FDA的孤儿药和快速通道认证资格","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"1102999674","title":"Esperion Therapeutics股价盘后下跌17%至2.55美元，此前公司宣布拟发行股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1102999674","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102999674?lang=zh_cn&edition=full","pubTime":"2025-10-08 04:36","pubTimestamp":1759869382,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics股价盘后下跌17%至2.55美元，此前公司宣布拟发行股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"1174936842","title":"Esperion Therapeutics针对Alkem、Aurobindo Pharma、Msn、Renata、Sandoz的专利诉讼仍在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=1174936842","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174936842?lang=zh_cn&edition=full","pubTime":"2025-10-03 20:03","pubTimestamp":1759492995,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics针对Alkem、Aurobindo Pharma、Msn、Renata、Sandoz的专利诉讼仍在进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"1164272152","title":"Esperion Therapeutics Inc.与Anda Filer、DR. Reddy's Laboratories达成和解协议，后者承诺在2040年4月19日前不销售Nexletol®（贝前列酸）和Nexlizet®（贝前列酸和依折麦布）仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1164272152","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164272152?lang=zh_cn&edition=full","pubTime":"2025-10-03 20:01","pubTimestamp":1759492885,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc.宣布与Anda Filer和DR. Reddy's Laboratories达成和解协议。根据协议条款，这两家公司承诺在2040年4月19日之前不会销售Nexletol®（贝前列酸）和Nexlizet®（贝前列酸和依折麦布）的仿制药版本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"1115093991","title":"Esperion Therapeutics Inc.合作伙伴Otsuka获得日本监管批准，可销售Nexletol®用于治疗高胆固醇血症","url":"https://stock-news.laohu8.com/highlight/detail?id=1115093991","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115093991?lang=zh_cn&edition=full","pubTime":"2025-09-19 20:01","pubTimestamp":1758283318,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc.的合作伙伴Otsuka已获得日本监管部门批准，可在日本市场销售Nexletol®，用于治疗高胆固醇血症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"1135418780","title":"Esperion Therapeutics Inc. 贝培度酸获推荐用于无法接受他汀类药物治疗以达成LDL-C目标的患者，推荐等级为I类B级","url":"https://stock-news.laohu8.com/highlight/detail?id=1135418780","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135418780?lang=zh_cn&edition=full","pubTime":"2025-08-29 20:05","pubTimestamp":1756469159,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. 贝培度酸获得推荐，用于无法接受他汀类药物治疗以达成低密度脂蛋白胆固醇(LDL-C)目标的患者群体。该推荐等级为I类B级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"1151843361","title":"Esperion Therapeutics的贝美前列酸在最新ESC/EAS血脂异常管理指南中获得1a级推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1151843361","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151843361?lang=zh_cn&edition=full","pubTime":"2025-08-29 20:03","pubTimestamp":1756469039,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc.宣布，其贝美前列酸药物在最新更新的欧洲心脏病学会/欧洲动脉粥样硬化学会(ESC/EAS)血脂异常管理指南中获得了1a级推荐。这一推荐等级代表了该药物在血脂异常治疗领域的重要地位和临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2518320835","title":"Esperion Therapeutics, Inc.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518320835","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518320835?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:52","pubTimestamp":1741618343,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时52分，Esperion Therapeutics, Inc.股票出现波动，股价大幅跳水5.03%。截至发稿，该股报1.61美元/股，成交量116.017万股，换手率0.59%，振幅5.92%。Esperion Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.97%。其相关个股中，Sonoma Pharmaceuticals, Inc.、Sunshine Biopharma Inc C/Wts 、Medicus Pharma Ltd.涨幅较大，Sonoma Pharmaceuticals, Inc.、Petros Pharmaceuticals, Inc.、苏轩堂较为活跃，换手率分别为1663.75%、24.02%、19.08%，振幅较大的相关个股有Sonoma Pharmaceuticals, Inc.、Alvotech C/Wts 、Scilex Holding Company C/Wts 10/11/2027 ，振幅分别为60.30%、41.21%、35.91%。Esperion Therapeutics, Inc.公司简介：Esperion Therapeutics Inc 是一家制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225223a26a4395&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225223a26a4395&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","ESPR","LENZ"],"gpt_icon":0},{"id":"2518423906","title":"Esperion Therapeutics, Inc.2024财年实现净利润-51.75百万美元，同比增加75.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518423906","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518423906?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449696,"startTime":"0","endTime":"0","summary":"3月9日，Esperion Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-51.75百万美元，同比增加75.24%；其中营业收入为3.32亿美元，同比增加186.21%，每股基本收益为-0.28美元。从资产负债表来看，Esperion Therapeutics, Inc.总负债7.33亿美元，其中短期债务1.05亿美元，资产负债比为0.47，流动比率为1.38。机构评级：截至2025年3月9日，当前有8家机构对Esperion Therapeutics, Inc.目标价做出预测，其中目标均价为6.62美元，其中最低目标价为2.00美元，最高目标价为16.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000312abef9912&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000312abef9912&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ESPR"],"gpt_icon":1},{"id":"2517944067","title":"Esperion Therapeutics, Inc.盘中异动 大幅下挫5.08%报1.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517944067?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:05","pubTimestamp":1741194354,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时05分，Esperion Therapeutics, Inc.股票出现波动，股价快速下挫5.08%。截至发稿，该股报1.68美元/股，成交量203.496万股，换手率1.03%，振幅6.72%。Esperion Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.50%。其相关个股中，Sunshine Biopharma Inc C/Wts 、Organogenesis Holdings Inc.、坎伯兰药业涨幅较大，Painreform Ltd.、Petros Pharmaceuticals, Inc.、Quantum Biopharma Ltd.较为活跃，换手率分别为21.43%、11.42%、6.29%，振幅较大的相关个股有坎伯兰药业、Alpha Teknova, Inc.、Medicus Pharma Ltd.，振幅分别为27.93%、16.89%、14.66%。Esperion Therapeutics, Inc.公司简介：Esperion Therapeutics Inc 是一家制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306010554989d6895&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306010554989d6895&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","ESPR"],"gpt_icon":0},{"id":"2516778266","title":"Esperion Therapeutics, Inc.盘中异动 股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516778266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516778266?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099028,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分，Esperion Therapeutics, Inc.股票出现异动，股价急速上涨5.06%。截至发稿，该股报1.66美元/股，成交量72.1156万股，换手率0.37%，振幅3.16%。Esperion Therapeutics, Inc.股票所在的制药行业中，整体跌幅为0.57%。其相关个股中，Optinose, Inc.、脑再生科技、Esperion Therapeutics, Inc.涨幅较大，大自然药业、Petros Pharmaceuticals, Inc.、Emergent Biosolutions Inc.较为活跃，换手率分别为4.07%、1.51%、1.39%，振幅较大的相关个股有Emergent Biosolutions Inc.、Optinose, Inc.、Medicus Pharma Ltd.，振幅分别为13.18%、10.25%、9.74%。Esperion Therapeutics, Inc.公司简介：Esperion Therapeutics Inc 是一家制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422370896394657&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422370896394657&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","ESPR"],"gpt_icon":0},{"id":"1145722208","title":"Esperion Therapeutics 2024年第四季度GAAP每股收益$(0.11)超出$(0.16)预期，销售额$69.11M超出$61.58M预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1145722208","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145722208?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:06","pubTimestamp":1741086414,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics  公布其季度每股亏损$，较分析师的共识预期$高出31.25%。公司季度销售额为$69.11M，超出分析师共识预期$61.58M，高出12.22%。与去年同期的销售额$32.25M相比，这增长了114.30%。以上内容来自Benzinga Earnings专栏，原文如下：Esperion $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 31.25 percent. This is a 78 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $69.11 million which beat the analyst consensus estimate of $61.58 million by 12.2","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Esperion Therapeutics 2024年第四季度GAAP每股收益$(0.11)超出$(0.16)预期，销售额$69.11M超出$61.58M预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR"],"gpt_icon":0},{"id":"2516265874","title":"Esperion Therapeutics, Inc.盘中异动 股价大跌5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516265874","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516265874?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:01","pubTimestamp":1741017699,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时01分，Esperion Therapeutics, Inc.股票出现波动，股价快速下挫5.88%。截至发稿，该股报1.60美元/股，成交量65.0638万股，换手率0.33%，振幅4.12%。Esperion Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.59%。其相关个股中，坎伯兰药业、Kiniksa Pharmaceuticals, Ltd.、Intercure Ltd.涨幅较大，Petros Pharmaceuticals, Inc.、苏轩堂、大自然药业较为活跃，换手率分别为17.45%、8.59%、6.87%，振幅较大的相关个股有Sunshine Biopharma Inc C/Wts 、Cyclo Therapeutics Inc C/Wts 11/12/2025、坎伯兰药业，振幅分别为35.16%、18.12%、17.49%。Esperion Therapeutics, Inc.公司简介：Esperion Therapeutics Inc 是一家制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000139abe65133&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000139abe65133&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","ESPR","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":-0.0817},{"period":"1month","weight":-0.0185},{"period":"3month","weight":0.1242},{"period":"6month","weight":2.1709},{"period":"1year","weight":0.6864},{"period":"ytd","weight":0.0027}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Esperion Therapeutics, Inc.于2008年1月在特拉华州注册成立。该公司是一家后期制药公司，专注于开发和商业化补充，方便，具有成本效益的每日一次口服疗法，用于治疗 LDL-C升高的患者。 通过科学和临床卓越以及对胆固醇生物学的深入理解，该公司有经验的脂质管理团队致力于开发新的LDL-C降低疗法，这将对减少全球心血管疾病或心血管疾病产生重大影响; 世界各地死亡的主要原因。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":-0.03675},{"month":2,"riseRate":0.5,"avgChangeRate":0.124334},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027865},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.028114},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.032489},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics Inc.","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics Inc.(ESPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Esperion Therapeutics Inc.(ESPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Esperion Therapeutics Inc.,ESPR,Esperion Therapeutics Inc.股票,Esperion Therapeutics Inc.股票老虎,Esperion Therapeutics Inc.股票老虎国际,Esperion Therapeutics Inc.行情,Esperion Therapeutics Inc.股票行情,Esperion Therapeutics Inc.股价,Esperion Therapeutics Inc.股市,Esperion Therapeutics Inc.股票价格,Esperion Therapeutics Inc.股票交易,Esperion Therapeutics Inc.股票购买,Esperion Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics Inc.(ESPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Esperion Therapeutics Inc.(ESPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}